Income statement
USD
Annual
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 1M | 3M | 1M | 1M | 550K |
| Gross Profit | 506K | 2M | 1M | 1M | 386K |
| Operating Income | -7M | -6M | -7M | -6M | -3M |
| EBITDA | -7M | -5M | -2M | -6M | -2M |
| Net Income | -6M | -5M | -3M | -6M | -4M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$7.41
-7.84% today
1Y Change
-86.93%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 249 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
SciSparc Ltd. (SPRC) is a Healthcare stock with listed on NASDAQ. The stock last traded around $7.41 and down 86.9% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of -54.6%, EPS growth of +91.4%, a dividend yield of 0.0%. What stands out right now is revenue -54.6%, EPS +91.4%, free cash flow +13.3% with operating margin -2156.9% and ROIC -782.0%. Valuation is more restrained than many high-expectation growth names at price/sales 0.5. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SPRC price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SPRC
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SPRC Max Drawdown
-95.85%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SPRC and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$550.0K
-48.6% YoY
FY Net Income
-$3.5M
+39.5% YoY
Free Cash Flow
-$4.3M
+15.5% YoY
Revenue Growth
-54.6%
EPS Growth
+91.4%
Gross Margin
21.9%
Net Margin
-1312.8%
Income statement
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 1M | 3M | 1M | 1M | 550K |
| Gross Profit | 506K | 2M | 1M | 1M | 386K |
| Operating Income | -7M | -6M | -7M | -6M | -3M |
| EBITDA | -7M | -5M | -2M | -6M | -2M |
| Net Income | -6M | -5M | -3M | -6M | -4M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 2M | 2M | 4M | 7M | 2M |
| Total Assets | 10M | 11M | 11M | 10M | 3M |
| Total Liabilities | 1M | 2M | 4M | 2M | 1M |
| Shareholder Equity | 8M | 8M | 6M | 8M | 1M |
| Total Debt | 46K | 76K | 27K | 504K | 465K |
| Net Debt | -1M | -2M | -4M | -6M | -1M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
4M
+14.9% YoY
Capital Expenditures
0
+100.0% YoY
Free Cash Flow
4M
+15.5% YoY
Key ratios
Gross Margin
21.9%
Operating Margin
-2156.9%
Net Margin
-1312.8%
ROE
-330.2%
Debt / Equity
-3.14x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.